Celera Licenses Protein IP for Lung Cancer Dx | GenomeWeb

NEW YORK (GenomeWeb News) – Celera said today that it has licensed the rights to use Medical Therapies Limited's patent portfolio for the protein midkine in its lung cancer diagnostics programs.

Under the exclusive license with Sydney-based Medical Therapies, Celera will pay up front and milestone payments and royalties on product sales over the life of the patents. Specific financial details were not disclosed by the firms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.